BUZZ-Oncolytics Biotech Inc: Presents mid-stage data on lead drug

Mon Jul 6, 2015 10:07am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian biotech's U.S.-listed shares up about 25 pct at 67 cents

** Says data from mid-stage study of experimental drug reolysin in combination with chemotherapy gemcitabine suggests increase in median overall survival

** Data indicates combination can also nearly double 1-year survival rates, raise 2-year survival rates by 5 times, compared with gemcitabine alone - COO Matt Coffey

** Up to Thursday's close, stock had fallen nearly 24 pct since April 29, when drug developer announced European regulator had granted reolysin "orphan drug status"